New chemotherapeutic approaches for the treatment of Chagas disease (American Trypanosomiasis)

Bibliography

• WORLD HEALTH ORGANIZATION: Tropical Disease Research. In: Thirteenth Programme Report, UNDP/World Bank/World Health Organization Programme for Research and Training in Tropical Diseases. World Health Organization, Geneva (1997).
   Google Scholar
• SCHMUICTIS GA: A Tripanossomiase Americana e sue impacto na sutide publica das Americas. In: Typanosoma cruzi e Doence de Chagas. Brener Z, Andrade Z, Barral-Netto M (Eds), Guanabara Koogan, Rio de Janeiro (2000):1–15.
   Google Scholar
• WORLD HEALTH ORGANIZATION: Control of Chagas Disease. Technical Reports Series (2002) 905:1–109.
   Google Scholar
• PINTO DIAS JC: Epidemiologia. In: Typanosoma cruzi e doence de Chagas. (2nd Ed.). Brener Z, Andrade Z, Barral-Netto C (Eds), Guanabara Koogan, Rio de Janeiro (1999):48–74.
   Google Scholar
• URBINA JA: Specific treatment of Chagas disease: current status and new developments. Curr. Op. Infect. Dis. (2001) 14:733–741.
   PubMedGoogle Scholar
• URBINA JA: Chemotherapy of Chagas Disease. Cum Pharm. Design (2002) 8:287–295.
   PubMed Web of Science ®Google Scholar
• DOCAMPO R: Recent developments in the chemotherapy of Chagas' disease. Cum Pharm. Design (2001) 7:1157–1164.
   PubMed Web of Science ®Google Scholar
• COURA JR, DE CASTRO SL: A critical review on Chagas disease chemotherapy. Mem. Inst. Oswald° Cruz (2002) 97:3–24.
   PubMed Web of Science ®Google Scholar
• CANQADO JR: Criteria of Chagas disease cure. Mem. Inst. Oswald° Cruz (1999) 94\(Supp1.1):331–336.
   Google Scholar
• BRENER Z, GAZZINELLI RT: Immunological control of Trypanosome cmzi infection and pathogenesis of Chagas' disease. Int. Arch. AllergyImmunol (1997) 114:103–110.
   PubMed Web of Science ®Google Scholar
• URBINA JA: Chemotherapy of Chagas' disease: the how and the why. I Ma Med. (1999) 77:332–338.
   Google Scholar
• HIRST SI, STAPLEY LA: Parasitology: the dawn of a new millenium. Parasitol Today (2000) 16:1–3.
   PubMedGoogle Scholar
• MOREL CM: Reaching maturity-25 years of the TDR. Parasitol Today (2000) 16:522–525.
   PubMedGoogle Scholar
• TROUILLER P, OLLIARO P, TORREELE E, ORBINSKI J, LAING R, FORD N: Drug development for neglected diseases: a deficient market and public-health policy failure. Lancet (2002) 359:2188–2194.
   PubMed Web of Science ®Google Scholar
• TARLETON RL, ZHANG L: Chagas disease ethiology: autoimmunity or parasite persistence? Parasitol Today (1999) 15:94–99.
   PubMedGoogle Scholar
• TARLETON RL: Parasite persistence in theaetiology of Chagas disease. Int.' Parasitol (2001) 31:550–554.
   PubMed Web of Science ®Google Scholar
• MCKERROW JH, MCGRATH ME, ENGEL JC: The cysteine proteinase of Trypanosome cruzias a model for antiparasite drug design. Parasitol Today (1995) 11:279–282.
   PubMedGoogle Scholar
• CAZZULO JJ: Proteinases of Trypanosomacruzi: potential targets for the chemotherapy of Chagas disease. CurcPharm.Design (2002) 2:1261–1271.
   Google Scholar
• CAZZULO JJ, STOKA V, TURK V: Themajor cysteine proteinase of Trypanosome cruzi: a valid target for chemotherapy of Chagas disease. CurcPharm.Design (2001) 7:1143–1156.
   Google Scholar
• ENGEL JC, DOYLE PS, HSIEH I, MCKERROW JH: Cysteine protease inhibitors cure experimental Trypanosma cruziinfection. I Exp. Med. (1998) 188:725–734.
   PubMed Web of Science ®Google Scholar
• •This is the first report of in vivo trypanocidal activity of cysteine protease inhibitors.
   Google Scholar
• ENGEL JC, DOYLE PS, MCKERROW JH: Trypanocidal effect of cysteine protease inhibitors in vitro and in vivo in experimental Chagas disease. Medicine (1999)59 (Suppla :171–175.
   Google Scholar
• DU X, HANSELL E, ENGEL JC, CAFFREY CR, COHEN FE, MCKERROW JH: Aryl ureas represent a new class of anti-trypanosomal agents. Chem. Biol. (2000) 7:733–742.
   PubMed Web of Science ®Google Scholar
• DU X, GUO C, HANSELL E et al.: Synthesis and structure-activity relationship study of potent trypanocidal thiosemicarbazone inhibitors of the trypanosomal cysteine protease cruzain. .1. Med. Chem. (2002) 45:2695–2707.
   Google Scholar
• URBINA JA: Sterol biosynthesis inhibitors for Chagas' disease. Cum Op. Anti-infect. Inv. Drugs (2000) 2:40–46.
   Google Scholar
• ••This review describes the first reports onparasitological cure of acute and chronic experimental Chagas disease, using novel triazole derivatives, inhibitors of sterol C14a demethylase.
   Google Scholar
• URBINA JA: Parasitological cure of Chagas disease: is it possible, is it relevant? Mem. Inst. Oswald° Cruz(1999) 94\(Supp1.1):349–355.
   Google Scholar
• URBINA JA, PAYARES G, MOLINA J et al: Cure of short- and long-term experimental Chagas disease using D0870. Science (1996) 273:969–971.
   PubMed Web of Science ®Google Scholar
• URBINA JA, PAYARES G, SANOJA C et al: Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Typanosoma cruzi strains. Intern. Antimicrob. Agents (2003) 21:39–48.
   Google Scholar
• MOLINA J, MARTINS-FILHO 0, BRENER Z, ROMANHA AJ, LOEBENBERG D, URBINA JA: Activity of the triazole derivative SCH 56592 (Posaconazole) against drug-resistant strains of the protozoan parasite Trypanosome (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob. Agents Chemother. (2000) 44:150–155.
   PubMed Web of Science ®Google Scholar
• MOLINA J, BRENER Z, ROMANHA AJ, URBINA JA: In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Typanosoma cruzi. Effects of immunosuppresion. Antimicrob. Chemother. (2000) 46:137–140.
   PubMed Web of Science ®Google Scholar
• URBINA JA, PAYARES G, SANOJA C, LIRA R, ROMANHA AJ: In vitro and in vivo activities of ravuconazole on Trypanosome cruzl the causative agent of Chagas disease. Intern.' Antimicrob. Agents (2003) 21:27–38.
   PubMed Web of Science ®Google Scholar
• MARTIN MB, ARNOLD WHEATH III HT, URBINAJA, OLDFIELD E: Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem. Biophys. Res. Comm. (1999) 263:754–758.
   PubMed Web of Science ®Google Scholar
• DUNFORD JE, THOMPSON K, COXON FP et al: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. PharmacoL Expel: Therapeutics (2001) 296:235–242.
   PubMed Web of Science ®Google Scholar
• MONTALVETTI A, BAILEY BN, MARTIN MB, SEVERIN GW, OLDFIELD E, DOCAMPO R: Bisphosphonates are potent inhibitors of Trypanosome cmzi farnesyl pyrophosphate synthase. Biol. Chem. (2001) 276:33930–33937.
   Google Scholar
• AMIN D, CORNELL SA, GUSTAFSON SKet al.: Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. I Lipid Res. (1992) 33:1657–1663.
   Google Scholar
• AMIN D, CORNELL SA, PERRONE MH, BILDER GE: 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as potent inhibitor of squalene synthase. Drug Res. (1996) 46:759–762.
   PubMed Web of Science ®Google Scholar
• RESZKA AA, HALASY-NAGY J, RODAN GA: Nitrogen-bisphosphonates block retinoblastoma phosphotylation and cell growth by inhibiting the cholesterol biosymthetic pathway in a keratinocyte model for esophageal irritation. MoL Pharinacol (2001) 59:193–202.
   PubMed Web of Science ®Google Scholar
• URBINA JA, CONCEPCION JL, CALDERA A, LIRA R, PAYARES G, SANOJA C: In vitro and in vivo activities of ER-27856, a novel squalene synthase inhibitor, against Trypanosoma cruzi, the causative agent of Chagas disease. ICAAC Abstracts (2002) 42:LB–25.
   Google Scholar
• DOCAMPO R, MORENO SNJ: Bisphosphonates as chemotherapeutic agents against Trypanosomatid and Apicomplexan parasites. Cuir. Drug Targets-Infec. Disord. (2001) 1:51–61.
   PubMedGoogle Scholar
• DOCAMPO R, MORENO SNJ: Acidocalcisome: a novel Ca2+ storage compartment in Trypanosomatids and Apicomplexan parasites. ParasitoL Today (1999) 15:443–448.
   PubMedGoogle Scholar
• DOCAMPO R, MORENO SNJ: The acidocalcisome. Mol. Biochein. ParasitoL (2001) 33:151–159.
   Google Scholar
• BUCKNER FS, GRIFFIN JH, WILSON AJ, VAN VOORHIS WC: Potent anti-Trypanosina cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob. Agents Cheinother. (2001) 45:1210–1215.
   PubMedGoogle Scholar
• •This is the first report of oxidosqualene cydase inhibitors as selective anti- Tcruzi agents.
   Google Scholar
• BUCKNER FS, NGUYEN LN, JOUBERT BM, MATSUDA SP: Cloning and expression of the Trypanosoma brucei lanosterol synthase gene. Ma Biochein. Parasitol (2000) 110:399–403.
   PubMedGoogle Scholar
• JOUBERT BM, BUCKNER FS, MATSUDA SP: Trypanosome and animal lanosterol synthases use different catalytic motifs. Org. Lett. (2001) 14:1957–1960.
   Google Scholar
• ZUCCOTTO F, MARTIN AC, LASKOWSKI RA, THORNTON JM, GILBERT IH: Dihydrofolate reductase: a potential drug target in trypanosomes and leishmania. I Comput. Aided Ma Des. (1998) 12:241–257.
   PubMed Web of Science ®Google Scholar
• GILBERT IH: Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes. Biochim. Biophys. Acta (2002) 587:249–257.
   Google Scholar
• RECHE P, ARREBOLA R, OLMO A, SANTI DV, GONZALEZ-PACANOWSKA D, RUIZ-PEREZ LM: Cloning and expression of the dihydrofolate reductase-thymidylate synthase gene from Trypanosoma cruzi. Mol. Biochein. Parasitol (1994) 65:247–258.
   PubMed Web of Science ®Google Scholar
• RECHE P, ARREBOLA R, SANTI DV, GONZALEZ-PACANOWSKA D, RUIZ-PEREZ LM: Expression and charecterization of the Trypanosoma cruzi dihydrofolate reductase domain. Ma Biochein. Parasitol (1996) 76:175–185.
   PubMedGoogle Scholar
• CROFT SL, HOGG J: Limited activity ofbacterial DNA topoisomerase II inhibitors against Leishmania donovani and Trypanosoma cruzi amastigotes in vitro. Trans. Roy Soc. Bop. Med. Hyg. (1988) 82:656.
   Google Scholar
• FURET YX, PECHERE JC: Newly documented antimicrobial activity of quinolones. Ear: I Clin. Microbiol Infect. Dis. (1991) 10:249–254.
   PubMedGoogle Scholar
• GONZALEZ-PERDOMO M, DE CASTRO SL, MEIRELLES MNL, GOLDENBERG S: Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors. Antimicrob. Agents Cheinother. (1990) 34:1707–1714.
   PubMedGoogle Scholar
• NENORTAS E, BURRI C, SHAPIRO TA: Antitrypanosomal activity of fluoroquinolones. Antimicrob. Agents Cheinother. (1999) 43:2066–2068.
   PubMed Web of Science ®Google Scholar
• FARRELL NP, WILLIAMSON J, MCLAREN DJ: Trypanocydal and anti-tumor activity of platinum-metal and platinum-metal-drug dual function complexes. Biochein. PharinacoL (1984) 33:961–971.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-DELGADO RA, LAZARDI K, RINCON L, URBINA JA, HUBERT AJ, NOELS AN: Toward a novel metal-based chemotherapy against tropical diseases. 1. Enhancement of the efficacy of clotrimazole against Trypanosoma cruzi by complexation to ruthenium in RuClgclotrimazole) 2. Med. Chem. (1993) 36:2041–2043.
   Google Scholar
• SANCHEZ-DELGADO RA, NAVARRO M, PEREZ H, URBINA JA: Towards a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium- and rhodium-chloroquine complexes. Med. Chem. (1996) 39:1095–1099.
   Google Scholar
• SANCHEZ-DELGADO RA, NAVARRO M, LAZARDI K et al.: Towards a novel metal based chemotherapy against tropical diseases. 4. Synthesis and characterization of new metal-clotrimazole complexes and evaluation of their activity against Trypanosoma cruzi. Inorg. Chim. Acta (1998) 275–276:528–540.
   Google Scholar
• PEREIRA-CHIOCCOLA VL, SCHENKMAN S: Biological role of Trypanosoma cruzitrans-sialidase. Biochein. Soc. Trans. (1999) 27:516–518.
   PubMed Web of Science ®Google Scholar
• FRASCH AC: Functional diversity in the trans-sialidase family and mucin families in Trypanosoma cruzi. ParasitoL Today (2000) 16:282–286.
   PubMedGoogle Scholar
• BUCHIAZZO A, AMAYA ME CREMONA ML, FRASCH AC: The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis. Mo/. Cell(2002) 10:757–768.
   PubMedGoogle Scholar
• VERCESI AE, DOCAMPO R: Sodium-proton exchange stimulates Ca2+ release from acidocalcisomes of Trypanosoma brucei. Biochein. J. (1996) 315:265–270.
   PubMedGoogle Scholar
• VERCESI AE, RODRIGUES CO, CATISTI R, DOCAMPO R: Presence of a Na±/H+ exchanger in acidocalcisomes of Leishmania donovani and their alkalinization by anti-leishmanial drugs. FEBS Lett. (2000) 12:203–206.
   Google Scholar